Mechanism of action
Furex contains Fluconazole, a broad-spectrum fungistatic antifungal. Its action is presented by an inhibitory effect on the enzyme 14-x-demethylase of cytochrome P450, with the consequent decrease in ergosterol, which is an essential constituent of the membrane of the fungus.
Furex is indicated in the treatment of the following diseases:
Cryptococcosis, including cryptococcal meningitis and infections at other sites (leg, lung and skin). It can be used to treat normal host patients, patients with acquired immunodeficiency syndrome (AIDS), with organ transplantation or with other causes of immunosuppression.
Systemic candidiasis, including candidemia, disseminated candidiasis, and other forms of invasive candidiasis, including infections of the peritoneum, endocardium, and respiratory and urinary systems.
Mucous candidiasis, including non-invasive oropharyngeal, bronchopulmonary infections, candiduria, mucocutaneous candidiasis, and chronic atrophic oral candidiasis (oral prosthetic ulcers).
Acute or recurrent vaginal yeast infection.
Dermatomycosis: tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor.
Deep endemic mycoses, including coccidioidomycosis, paracoccidioidomycosis, sporotrichosis, and histoplasmosis in immunocompromised patients.
Prevention of fungal infection in patients with some malignant process, and who are predisposed to such infections as a result of cytotoxic chemotherapy or radiotherapy.
Recognized hypersensitivity to Fluconazole or other triazole derivatives.
Its use during pregnancy should be avoided, except in patients with some severe, or life-threatening fungal infection, for whom the use of Fluconazole may have more potential benefit than possible risk to the fetus. its use is not recommended during lactation. Fluconazole has been associated in rare cases of serious liver toxicity. Cases of Fluconazole treatments associated with hepatotoxicity have been observed, with no obvious relationship to total daily dose, duration of therapy, sex, or age. Fluconazole hepatotoxicity has generally been reversible with discontinuation of therapy. In patients who report abnormal liver function tests during treatment with Fluconazole, they should be monitored for more serious liver damage. If this occurs, therapy should be discontinued.
The most frequent adverse effects observed with the administration of Furex are: Nausea, abdominal pain, diarrhea, flatulence, rash, and anaphylaxis has been reported eventually.
It can happen with:
Coumarin anticoagulants: Increases prothrombin time.
Cyclosporine: Increases the plasma concentration of cyclosporine.
Phenytoin: Increases the plasma concentration of phenytoin.
Rifampicin: The pharmacokinetics of both drugs and the half-life of Fluconazole that decreases by 20% are affected.
Antidiabetic agents, sulfonylurea: Increase the plasma concentration of drugs and reduce the metabolism of antidiabetic agents.
Thiazide diuretics: Increase the plasma concentration of Fluconazole.
Each coated tablet contains:
Fluconazole 150 mg
Posology and administration
Route of administration: Oral.
Vaginal yeast infection: Furex 150mg, one tablet as a single dose.
Onychomycosis: Furex 150 mg, one tablet a week until mycological cure (8-16 weeks).
Dermatomycosis including tinea pedis: the usual dose is 150 mg once a week, for 2 to 4 weeks, although there are cases that may require up to 6 weeks. In the case of AIDS patients, as a prevention of relapse of cryptococcal meningitis, a daily dose of 150 mg can be administered indefinitely.
Box containing a blister with a 150mg coated tablet.
Keep in a cool place (below 30 °C).